In conclusion, our study did not meet its primary end point; compared with osimertinib monotherapy, osimertinib and bevacizumab combination treatment failed to increase the 1-year PFS of patients with EGFR-mutated advanced NSCLC with malignant pleural or pericardial effusion. Here, EGFR is linked to pericardial effusion.